NOD1/2 signaling in macrophages drives adaptive immune resistance in cancer.
Blocking immune checkpoint signals in immune cells could enhance cancer immunotherapy by restoring T cell function.
This mechanistic study demonstrated that NOD1/2 receptor signaling in tumor-associated macrophages within the TME drives immune resistance by suppressing effector T cells through immunosuppressive mediator upregulation, revealing a previously underappreciated innate immune checkpoint. Published in Signal Transduction and Targeted Therapy, findings suggest NOD1/2 as a tractable therapeutic target to enhance immunotherapy responses.
What the study was
- Study design
- Experimental mechanistic study (in vitro and in vivo)
- Category
- Other
- Maturity
- Exploratory
- Journal
- Signal Transduct Target Ther
Why it surfaced
Novel NOD1/2-macrophage immune resistance mechanism; published in high-impact Signal Transduct Target Ther; mechanistically actionable for next-generation immunotherapy target intelligence.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.